Global OTC leader grows in China
This article was originally published in The Tan Sheet
Executive Summary
Japanese firm Taisho Pharmaceutical, an OTC manufacturer and a majority stakeholder of Chinese firm Shanghai Dazhengli Health Care, purchased the 15 percent of the firm held by the Guan Shen Yuan Group for 14.7994 million yuan ($2.2 million at Sept. 24 conversion rates). Taisho set up Shanghai Dazhengli Health Care in 1997 to sell its Libogen products in China. Shanghai Dazhengli can produce more than 20 million bottles of Lipovitan D nutrient drink annually. Taisho wants to expand its production and sales in China from Shanghai
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.